Arvinas (NASDAQ:ARVN) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Arvinas (NASDAQ:ARVN) in a research note released on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $13.00 price target on the stock. HC Wainwright also issued estimates for Arvinas’ Q4 2026 earnings at ($0.88) EPS, FY2026 earnings at $0.00 EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($2.44) EPS, FY2028 earnings at ($2.70) EPS, FY2029 earnings at ($1.74) EPS and FY2030 earnings at ($0.72) EPS.

Several other research firms have also issued reports on ARVN. Wall Street Zen raised shares of Arvinas from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. BTIG Research reiterated a “buy” rating and issued a $18.00 price target on shares of Arvinas in a report on Tuesday, August 4th. Wells Fargo & Company lowered Arvinas from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $15.00 to $11.00 in a research report on Tuesday, August 4th. Morgan Stanley set a $10.00 price objective on Arvinas in a research note on Monday, August 10th. Finally, Weiss Ratings downgraded Arvinas from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.18.

Arvinas Trading Down 11.7%

ARVN stock opened at $6.55 on Tuesday. The stock has a 50-day moving average price of $7.92 and a two-hundred day moving average price of $9.60. Arvinas has a 12-month low of $6.52 and a 12-month high of $14.51. The company has a market cap of $428.96 million, a PE ratio of -27.29 and a beta of 1.81.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.10. Arvinas had a negative return on equity of 2.00% and a negative net margin of 3.45%. The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $12.39 million. During the same period in the prior year, the firm posted ($0.48) earnings per share. The firm’s revenue was down 98.8% on a year-over-year basis. Equities analysts forecast that Arvinas will post 0.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Arvinas

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE acquired a new stake in shares of Arvinas during the 2nd quarter worth approximately $2,102,000. Man Group plc acquired a new position in Arvinas during the 2nd quarter valued at approximately $2,128,000. GSA Capital Partners LLP acquired a new position in Arvinas during the 2nd quarter valued at approximately $1,182,000. Squarepoint Ops LLC grew its stake in Arvinas by 760.3% during the 2nd quarter. Squarepoint Ops LLC now owns 201,822 shares of the company’s stock worth $1,677,000 after buying an additional 178,362 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Arvinas during the 2nd quarter worth $1,388,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $13 price target, offering a bullish counterpoint to the stock’s recent weakness. Arvinas Stock Picked Up by Analysts at HC Wainwright
• Neutral Sentiment: Arvinas plans to present preliminary Phase 1 dose-escalation data for ARV-393, its experimental BCL6 degrader. The announcement could draw investor attention, but the article provides no clinical results to assess. Arvinas to Present Preliminary Clinical Data for ARV-393
• Negative Sentiment: HC Wainwright’s estimates anticipate losses of $2.44 per share in 2027 and $2.70 in 2028, followed by continued losses through 2030. Those projections may weigh on sentiment despite the firm’s positive rating.

About Arvinas

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.